Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | BACE1 | P56817 | 2/20 | 0.45 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31211096 | 0.85 | ACHE (0.47) | FUCA1SIGMAR1ACHEBCHEBACE1 | |
| SCHEMBL4619365 | 0.83 | FUCA1 (0.51) | FUCA1SIGMAR1ACHEBCHEBACE1 | |
| SCHEMBL13102792 | 0.83 | FUCA1 (0.51) | FUCA1SIGMAR1ACHEBCHEBACE1 | |
| SCHEMBL1814808 | 0.83 | ACHE (0.55) | FUCA1SIGMAR1ACHEBCHEBACE1 | |
| SCHEMBL13117177 | 0.82 | FUCA1 (0.42) | FUCA1SIGMAR1ACHEBCHEBACE1 | |
| SCHEMBL16759827 | 0.80 | FUCA1 (0.64) | FUCA1SIGMAR1ACHEALDH1A1MC4R | |
| SCHEMBL16775256 | 0.80 | FUCA1 (0.64) | FUCA1SIGMAR1ACHEALDH1A1MC4R | |
| SCHEMBL19700424 | 0.79 | HTR4 (0.49) | FUCA1SIGMAR1ACHEHTR4ALDH1A1 | |
| SCHEMBL8259127 | 0.79 | FUCA1 (0.47) | FUCA1SIGMAR1ACHEBCHEBACE1 | |
| SCHEMBL4898687 | 0.78 | HTR4 (0.54) | FUCA1SIGMAR1HTR4S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | FUCA1 2221/4885SIGMAR1 1759/4885ACHE 1647/4885 |
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | FUCA1 3050/4885SIGMAR1 848/4885ACHE 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.